Skip to main content

Amgen drug patent challenge slices $2B off Alexion's market cap

Alexion's finances rely heavily on its rare disease drug Soliris. The drug is the source of 80 percent of Alexion's annual revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.